Thanks for posting that tparadise! However it seems that all of Exubera's shortcomings have been remedied by AFREZZA.

Big bong, tiny whistle sized inhaler

Not covered by insurance, MNKD has been in discussions for years with big insurance companies such as Unitedhealth positioning for rapidly making Tier II on the formulary

No new medical benfits over existing therapies, 1st and only in class ultra rapid acting insulin

Non industry standard dosing, industry standard dosing understood by Physicans Nurses and Patients

Complex device to operate required lots of medical professionals valuable time, Simple disposable device with no moving parts a 5 year old can use requiring no costly medical professional hand holding

Non linear dosing cartidges, Linear dosing cartridges

Botched product rollout, State of the art high speed production facilities support $4B sales per year initially and quickly expandable--$10 Billion worth of insulin inventory already on hand for a mere few million bucks & will have experienced partner

Complex titration required, Little/no titration required

The list goes on and on... Plus we have Alfred Mann on our side! I have no concerns at all.

Here is a good video of the inferior Pfizer Exubera bong in action:

http://www.youtube.com/watch?v=vU1gVsul0ME